CD8A and glioblastoma: Our examination through in vivo [89Zr]-CD8 minibody ImmunoPET imaging did not show a significant change in intratumoral CD8+ cell infiltration, based on SUVpeak TBR, following single agent M002 oHSV one-week post-therapy, which differs from previously published literature on CD8-targeted cys-diabody PET imaging of M002 virotherapy in preclinical GBM 31.